Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS)

CNY 19.28

(0.47%)

Market Cap (In CNY)

1.8 Billion

Revenue (In CNY)

497.29 Million

Net Income (In CNY)

40.05 Million

Avg. Volume

412.25 Thousand

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
12.83-25.85
PE
-
EPS
-
Beta Value
0.486
ISIN
CNE1000043R4
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Mr. Xiangting Cai
Employee Count
-
Website
https://www.gzlbp.com
Ipo Date
2020-08-20
Details
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China. It offers pathological diagnostic reagents and ancillary equipment, including liquid-based cytology, such as gynecological series, non-gynecological series, and equipment; fluorescence in situ hybridization products for various applications in breast, bladder, lung, cervical, prostate, and thyroid cancer; and neuroblastoma, soft tissue sarcoma, other solid tumors, prenatal screening and abortion, oligodendrocytes tumor, lymphoma, multiple myeloma, chronic myelogenous and lymphocytic leukemia, myelodysplastic syndromes, acute myeloid leukemia, and acute lymphoblastic leukemia. The company also provides immunohistochemistry products, which comprise antibodies, detection systems, repair systems, complementary products, and immunohistochemistry kit, as well as molecular genetic diagnosis products. Guangzhou LBP Medicine Science & Technology Co., Ltd. was founded in 2005 and is based in Guangzhou, China.